Summary of GMED Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $759.9 million, up 27% year-over-year (25.5% on a constant currency basis).

Base Business Revenue: $677.2 million, growing 13.2% year-over-year.

Non-GAAP EPS: $1.12, a 64.7% increase from the prior year.

GAAP Net Income: $124.3 million, with GAAP EPS of $0.90.

Adjusted Gross Profit Margin: 69.2%, up from 67.3% in the prior year.

Cash and Marketable Securities: $799.3 million as of March 31, 2026.

Nevro Revenue: $82.7 million, down 17.1% sequentially from Q4 2025.

2Strategic Updates and Business Highlights

U.S. Spine Business: Grew 10% for the third consecutive quarter, contributing to overall strength in the domestic market.

International Spine Business: Increased by 16.4% as reported, attributed to improved supply chain conditions.

Enabling Technologies: Revenue of $26.9 million, growing 21% year-over-year, with a shift towards more flexible leasing and rental models.

Product Launches: Received FDA 510(k) clearance for patient-specific Scripps spacer and rod systems, enhancing the product portfolio.

Trauma Business: Posted a 34% increase, driven by strong demand for the Anthem elbow plating system and the PRECICE limb lengthening portfolio.

3Forward Guidance and Outlook

2026 Revenue Guidance: Reaffirmed at $3.18 billion to $3.22 billion, indicating growth of 8.2% to 9.6% over 2025.

Non-GAAP EPS Guidance: Increased to $4.70 to $4.80, up from the previous range of $4.40 to $4.50, reflecting improved margin expectations.

Long-term Gross Margin Target: Aiming for mid-70s adjusted gross margin, with expectations for gradual improvement throughout the year.

4Bad News, Challenges, or Points of Concern

Nevro Business: Experienced a revenue decline due to structural changes in sales and marketing, anticipated to continue impacting results in the near term.

Competitive Pressures: Increased competition in the robotics space, leading to elongated deal closure times.

Market Dynamics: The company noted potential lumpiness in revenue from the Nevro business and a cautious approach to revenue guidance, reflecting uncertainties in the enabling technologies segment.

5Notable Q&A Insights

Revenue Guidance: Management expressed confidence in their revenue guidance despite acknowledging potential headwinds from Nevro and changes in enabling tech sales strategies.

Market Share Gains: Most growth in U.S. Spine attributed to market share gains rather than overall market growth, which is estimated at 3% to 3.5%.

Competitive Landscape: The company remains well-positioned against competitors, particularly Medtronic, with a strong pipeline and continued focus on innovative product offerings.

Operational Focus: Emphasis on maintaining operational discipline and leveraging manufacturing efficiencies to achieve long-term profitability goals. Overall, GMED reported a strong start to 2026, with significant revenue growth and margin expansion, while navigating challenges related to the integration of Nevro and competitive pressures in the market.